Guggenheim Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Guggenheim Capital’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14,020	Closed	-$212K	–	2033
2022 Q3	$212K	Buy	+14,020	New	+$163K	﹤0.01%	1778
2018 Q2	–	Sell	-5,324	Closed	-$289K	–	2674
2018 Q1	$289K	Buy	5,324 +258	+5%	+$14.4K	﹤0.01%	2541
2017 Q4	$303K	Sell	5,066 -1,606	-24%	-$97.4K	﹤0.01%	2489
2017 Q3	$324K	Buy	+6,672	New	+$364K	﹤0.01%	2525
2017 Q1	–	Sell	-34,135	Closed	-$1.29M	–	2952
2016 Q4	$1.29M	Buy	34,135 +1,384	+4%	+$52.3K	﹤0.01%	1998
2016 Q3	$1.24M	Buy	+32,751	New	+$722K	﹤0.01%	1961

Guggenheim Capital's AERI Position: Q4 2022 in Review

Guggenheim Capital sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 14,020 shares — an estimated $212K sold.

Guggenheim Capital first reported a position in AERI in Q3 2016 and held it in 6 quarters. The position peaked at $1.29M in Q4 2016. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

Guggenheim Capital reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Guggenheim Capital sold 14,020 Aerie Pharmaceuticals shares in Q4 2022, an estimated $212K.
Guggenheim Capital first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 6 quarters.
Guggenheim Capital's Aerie Pharmaceuticals position peaked at $1.29M in Q4 2016.
0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Guggenheim Capital's 13F filing for Q4 2022, filed 14 Feb 2023.